← all works
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Sinusitis and nasal conditions
- Field
- Medicine
- Canadian institutions
- Centre Hospitalier de l’Université de Montréal
- Funders
- —
- Keywords
- MedicineDupilumabNasal polypsPlaceboInternal medicinePlacebo-controlled studySinusitisClinical endpointRandomized controlled trialAsthmaChronic rhinosinusitisSurgeryDouble blindPathology
- Has abstract in OpenAlex
- no